Harrington Investments INC purchased a new position in Gilead Sciences, Inc. (NASDAQ:GILD) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 22,784 shares of the biopharmaceutical company’s stock, valued at approximately $1,846,000. Gilead Sciences accounts for about 1.8% of Harrington Investments INC’s investment portfolio, making the stock its 24th largest position.
Other institutional investors and hedge funds have also bought and sold shares of the company. Adviser Investments LLC lifted its holdings in shares of Gilead Sciences by 2.4% during the third quarter. Adviser Investments LLC now owns 66,792 shares of the biopharmaceutical company’s stock valued at $5,411,000 after purchasing an additional 1,571 shares in the last quarter. Augustine Asset Management Inc. bought a new position in shares of Gilead Sciences during the third quarter valued at $4,144,000. Bartlett & Co. LLC lifted its holdings in shares of Gilead Sciences by 3.7% during the third quarter. Bartlett & Co. LLC now owns 302,079 shares of the biopharmaceutical company’s stock valued at $24,474,000 after purchasing an additional 10,740 shares in the last quarter. Whittier Trust Co. of Nevada Inc. lifted its holdings in shares of Gilead Sciences by 1.0% during the third quarter. Whittier Trust Co. of Nevada Inc. now owns 102,715 shares of the biopharmaceutical company’s stock valued at $8,322,000 after purchasing an additional 996 shares in the last quarter. Finally, Whittier Trust Co. lifted its holdings in shares of Gilead Sciences by 3.9% during the third quarter. Whittier Trust Co. now owns 169,995 shares of the biopharmaceutical company’s stock valued at $13,773,000 after purchasing an additional 6,459 shares in the last quarter. 75.94% of the stock is currently owned by hedge funds and other institutional investors.
In other news, insider John F. Milligan sold 220,000 shares of the company’s stock in a transaction that occurred on Monday, November 13th. The stock was sold at an average price of $72.88, for a total value of $16,033,600.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider John C. Martin sold 73,333 shares of the company’s stock in a transaction that occurred on Wednesday, November 1st. The shares were sold at an average price of $75.13, for a total value of $5,509,508.29. Following the completion of the sale, the insider now owns 3,070,099 shares of the company’s stock, valued at $230,656,537.87. The disclosure for this sale can be found here. Insiders sold 461,666 shares of company stock valued at $34,072,567 over the last 90 days. Company insiders own 1.30% of the company’s stock.
GILD has been the subject of a number of research reports. Leerink Swann reiterated a “market perform” rating and set a $87.00 price objective (up previously from $82.00) on shares of Gilead Sciences in a research report on Wednesday, September 20th. Mizuho restated a “buy” rating on shares of Gilead Sciences in a research report on Friday, September 29th. Jefferies Group restated a “hold” rating and issued a $93.00 price target on shares of Gilead Sciences in a research report on Wednesday, October 4th. Bank of America reduced their price target on Gilead Sciences from $87.00 to $86.00 and set a “neutral” rating for the company in a research report on Wednesday, October 4th. Finally, Oppenheimer began coverage on Gilead Sciences in a research report on Thursday, October 5th. They set a “market perform” rating for the company. Two investment analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Gilead Sciences currently has an average rating of “Buy” and an average target price of $85.03.
Shares of Gilead Sciences, Inc. (GILD) traded down $0.04 during trading on Friday, hitting $79.02. The company had a trading volume of 6,342,448 shares, compared to its average volume of 8,150,000. The company has a current ratio of 3.68, a quick ratio of 3.56 and a debt-to-equity ratio of 1.10. Gilead Sciences, Inc. has a 1 year low of $63.76 and a 1 year high of $86.27. The stock has a market cap of $103,190.00, a price-to-earnings ratio of 8.99, a PEG ratio of -1.68 and a beta of 1.13.
Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $2.27 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $2.13 by $0.14. Gilead Sciences had a return on equity of 57.15% and a net margin of 42.22%. The company had revenue of $6.51 billion during the quarter, compared to analyst estimates of $6.40 billion. During the same period in the previous year, the business earned $2.75 EPS. Gilead Sciences’s quarterly revenue was down 13.2% on a year-over-year basis. sell-side analysts anticipate that Gilead Sciences, Inc. will post 8.53 earnings per share for the current fiscal year.
The business also recently declared a quarterly dividend, which was paid on Thursday, December 28th. Stockholders of record on Friday, December 15th were given a $0.52 dividend. The ex-dividend date was Thursday, December 14th. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.63%. Gilead Sciences’s dividend payout ratio (DPR) is presently 23.66%.
ILLEGAL ACTIVITY WARNING: “Harrington Investments INC Acquires Shares of 22,784 Gilead Sciences, Inc. (GILD)” was first reported by The Lincolnian Online and is the property of of The Lincolnian Online. If you are accessing this piece of content on another website, it was stolen and reposted in violation of U.S. & international copyright law. The original version of this piece of content can be viewed at https://www.thelincolnianonline.com/2018/01/13/harrington-investments-inc-invests-1-85-million-in-gilead-sciences-inc-gild-stock-updated-updated.html.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.